What is the 13F Pro Quality Score for APLS?

13F Pro ranks Apellis Pharmaceuticals, Inc. (APLS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View APLS's current score at https://13fpro.ai/company/APLS (free sign-up required for the full ranking).

Which hedge funds own the most APLS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of APLS include BlackRock,, Avoro Capital Advisors, MORGAN STANLEY. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/APLS as soon as new 13F filings post.

Where does 13F Pro source APLS data?

All Apellis Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Apellis Pharmaceuticals, Inc. files with the SEC under CIK 1492422. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is APLS in?

Apellis Pharmaceuticals, Inc. (APLS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is APLS research updated on 13F Pro?

APLS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Apellis Pharmaceuticals, Inc.(APLS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1492422 APLS stock profile & AI dashboard →

13F Pro Quality Score

62.5/100

Rank #709 of 2,961 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

92.8/100

Profitability

75.4/100

Balance Sheet

91.9/100

Earnings Quality

52.6/100

Free Cash Flow

36.8/100

Revenue Scale

51.7/100

Dilution Risk

15.9/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why APLS Scores 60/100

exact factor attribution · 2026-08-29

APLS's composite is driven by revenue growth and capital efficiency, held back by institutional flow and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+8.8 pts

94th pct

Capital efficiency

+3.9 pts

89th pct

Profitability

+3.5 pts

73th pct

Scale

+0.8 pts

55th pct

Earnings quality

+0.2 pts

52th pct

Earnings growth

-1.0 pts

30th pct

Shareholder dilution

-1.7 pts

16th pct

Free cash flow

-2.1 pts

36th pct

Institutional flow

-2.5 pts

0th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

APLS Stock Analysis & AI Quality Score

Data updated 2026-08-29

AI stock analysis and institutional research for Apellis Pharmaceuticals, Inc. (APLS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores APLS at 62.5/100 on a 32-signal composite quality model, placing it at rank #709 of 2,961 stocks — the top 25% of the AI-ranked universe. APLS scores in the top quartile across revenue growth (92.8), balance sheet strength (91.9), profitability (75.4). Areas of concern include free cash flow (36.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 15.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Apellis Pharmaceuticals, Inc. reports quarterly revenue of $268.3M, net income of $18.7M, an operating margin of 9.9%. Top institutional holders of APLS by reported 13-F value include BlackRock, Avoro Capital Advisors, MORGAN STANLEY, based on the most recent SEC filings. APLS trades on the Nasdaq exchange and files with the SEC under CIK 1492422. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate APLS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Apellis Pharmaceuticals, Inc. directly from SEC EDGAR. Apellis Pharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 15 and 67 since 2021, currently 62.5 — an improving long-term trajectory across 67 quarterly and live scoring snapshots.

✦

Fun facts about Apellis Pharmaceuticals, Inc.

Quirks, history, and lore behind APLS — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · mid-cap · listed on Nasdaq · headquartered in Massachusetts.
2
The Numbers
Annual revenue in the low hundreds of millions and climbing fast, driven almost entirely by one commercial product launched in the early 2020s.
3
The History
Founded in 2009, the company spent over a decade in the lab before cracking one of medicine's most stubborn targets: the complement system, a branch of innate immunity gone haywire.
4
The Secret
Its drugs work by blocking complement protein C3, a chokepoint upstream of where nearly every other complement drug in the industry aims — giving it a potentially broader mechanism than rivals.
5
The Lore
Its first approved drug targets geographic atrophy, the advanced, vision-robbing form of dry age-related macular degeneration — a condition that had no approved treatment for decades.
6
The Giveaway
The drug is called Syfovre, it's injected directly into the eye, and the company's ticker — APLS — is a nod to the complement protein at the heart of everything it does.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$268.3M

Net Income

Q1 2026

$18.7M

Operating Margin

Q1 2026

9.9%

ROIC

Q1 2026

25.5%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+28.5% YoY

$1.00BFY 2025

FY22 $75.4MFY23 $396.6MFY24 $781.4MFY25 $1.00B

Net Income

+111.3% YoY

$22.4MFY 2025

FY22 $-652.2MFY23 $-528.6MFY24 $-197.9MFY25 $22.4M

Operating Income

+133.6% YoY

$55.4MFY 2025

FY22 $-594.6MFY23 $-517.1MFY24 $-165.0MFY25 $55.4M

EPS (Diluted)

+112.5% YoY

$0.20FY 2025

FY22 $-6.15FY23 $-4.45FY24 $-1.60FY25 $0.20

Total Assets

+21.5% YoY

$1.08BFY 2025

FY22 $760.2MFY23 $788.7MFY24 $885.1MFY25 $1.08B

Total Debt

—FY 2025

FY22 $92.7MFY23 $93.0MFY24 —FY25 —

Op. Cash Flow

+151.6% YoY

$45.3MFY 2025

FY22 $-513.7MFY23 $-594.7MFY24 $-87.9MFY25 $45.3M

Free Cash Flow

+151.0% YoY

$45.0MFY 2025

FY22 $-515.3MFY23 $-595.5MFY24 $-88.3MFY25 $45.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.00B +28.5%	$781.4M +97.0%	$396.6M +425.8%	$75.4M +13.3%	$66.6M -73.4%	$250.6M
Net Income	$22.4M +111.3%	$-197.9M +62.6%	$-528.6M +18.9%	$-652.2M +12.6%	$-746.4M -116.4%	$-344.9M
Operating Income	$55.4M +133.6%	$-165.0M +68.1%	$-517.1M +13.0%	$-594.6M -10.9%	$-536.3M -150.9%	$-213.7M
EPS (Diluted)	$0.20 +112.5%	$-1.60 +64.0%	$-4.45 +27.6%	$-6.15 +30.4%	$-8.84 -92.6%	$-4.59
Total Assets	$1.08B +21.5%	$885.1M +12.2%	$788.7M +3.8%	$760.2M -13.8%	$881.8M -8.2%	$960.6M
Total Debt	—	—	$93.0M +0.3%	$92.7M	—	—
Operating Cash Flow	$45.3M +151.6%	$-87.9M +85.2%	$-594.7M -15.8%	$-513.7M +8.8%	$-563.1M -250.9%	$-160.5M
Free Cash Flow	$45.0M +151.0%	$-88.3M +85.2%	$-595.5M -15.6%	$-515.3M +8.7%	$-564.2M -240.1%	$-165.9M

Get alerted when APLS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Apellis Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of APLS

BlackRock, Inc.
$544.6M13,536,964 sh
Avoro Capital Advisors LLC
$491.7M12,222,222 sh
MORGAN STANLEY
$404.0M10,042,399 sh
STATE STREET CORP
$275.4M6,844,990 sh
UBS Group AG
$249.7M6,206,681 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$217.4M5,404,559 sh
Pentwater Capital Management LP
$211.2M5,250,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$191.9M4,768,944 sh
Deep Track Capital, LP
$182.3M4,532,374 sh
Point72 Asset Management, L.P.
$168.3M4,183,918 sh

Fund	Value	Shares
BlackRock, Inc.	$544.6M	13,536,964
Avoro Capital Advisors LLC	$491.7M	12,222,222
MORGAN STANLEY	$404.0M	10,042,399
STATE STREET CORP	$275.4M	6,844,990
UBS Group AG	$249.7M	6,206,681
VANGUARD PORTFOLIO MANAGEMENT LLC	$217.4M	5,404,559
Pentwater Capital Management LP	$211.2M	5,250,000
VANGUARD CAPITAL MANAGEMENT LLC	$191.9M	4,768,944
Deep Track Capital, LP	$182.3M	4,532,374
Point72 Asset Management, L.P.	$168.3M	4,183,918

Companies Similar to APLS

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

MASI

MASIMO CORP

AI score

Very similar · 1 shared holders

CIBRA Capital Ltd

OneStream, Inc.

AI score

Shared smart-money ownership · 2 shared holders

CIBRA Capital Ltd EFG Asset Management (North America) Corp.

FOLD

AMICUS THERAPEUTICS, INC.

AI score

Shared smart-money ownership · 2 shared holders

CIBRA Capital Ltd Point72 Hong Kong Ltd

ACLX

Arcellx, Inc.

AI score

Shared smart-money ownership · 1 shared holders

CIBRA Capital Ltd

SNCY

Sun Country Airlines Holdings, LLC

AI score

Shared smart-money ownership · 1 shared holders

CIBRA Capital Ltd

HOLX

HOLOGIC INC

AI score

Similar quality profile · 2 shared holders

CIBRA Capital Ltd HAP TRADING, LLC

MCW

Mister Car Wash, Inc.

AI score

Shared smart-money ownership · 1 shared holders

CIBRA Capital Ltd

DHIL

DIAMOND HILL INVESTMENT GROUP INC

AI score

Shared smart-money ownership · 1 shared holders

CIBRA Capital Ltd

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put APLS on your watchlist

Track score changes the day Apellis Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is APLS a good stock to buy?

13F Pro's AI-powered analysis of Apellis Pharmaceuticals, Inc. (APLS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for APLS are available on the APLS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. APLS is classified as a mid company.

Which hedge funds own APLS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling APLS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Apellis Pharmaceuticals, Inc.'s investment landscape.